CIML NK cell therapy for post-transplant MPN relapse
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-17 — Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation: Early-phase clinical trial launched testing preemptive IV infusion of cytokine-induced memory-like (CIML) NK cells supported by subcutaneous IL-2 after allo-HSCT to prevent relapse in AML, MDS, and MDS/MPN overlap syndrome — first-in-class preemptive (rather than salvage) use in this setting. (novelty: 4)
Open questions
Related
Contributing findings
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
17-jun-2026
novelty 4
per-area 4
strengthens